Ventyx biosciences reports second quarter 2023 financial results and highlights recent corporate progress

Completed enrollment in the phase 2 trial of vtx002 (s1p1r modulator) in ulcerative colitis and the phase 2 trial of vtx958 (tyk2 inhibitor) in plaque psoriasis, with topline readouts expected in q4 2023
VTYX Ratings Summary
VTYX Quant Ranking